HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Helix BioMedix acquires stake in NuGlow

This article was originally published in The Rose Sheet

Executive Summary

Developer of bioactive peptides has acquired 30% ownership interest in NuGlow Cosmeceuticals, LLC, according to July 8 release. In addition, under a three-year supply agreement, Helix BioMedix will provide NuGlow with finished products including private-label cosmeceutical, sun-care and acne-care products. "Their advanced line of peptides and superior formulations will allow us to expand our offerings significantly," says NuGlow CEO Steven Sheiner. Helix President and CEO R. Stephen Beatty states: "NuGlow has established a tested, cost-effective and proven direct-response model that I believe will increase the value proposition for the commercialization of Helix BioMedix technologies." Helix expects that deal will enable it to reach a younger consumer than it currently captures with its Striking Skin Care line. Initial marketing campaign by NuGlow is anticipated to launch in the fall, targeting women 28 to 50 years of age
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS017053

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel